Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility randomized trial of CTD versus stem cell transplantation or Mel-Dex in systemic AL amyloidosis
ISRCTN34235460Phase 3Completed
- Sponsor
- University College London
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, thalidomide, dexamethasone and melphalan in light-chain amyloidosis (4 arms), sponsored by University College London. Primary endpoints: Clonal response, Toxicity and safety and 1 more. Started Jan 2007; status: completed.
02
Drugs
cyclophosphamidethalidomidedexamethasonemelphalan
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ISRCTN34235460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN34235460.